Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Total Non-Current Liabilities (2018 - 2025)

BioNexus Gene Lab's Total Non-Current Liabilities history spans 8 years, with the latest figure at $116899.0 for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $116899.0 for Q4 2025, down 26.82% from a year ago — trailing twelve months through Dec 2025 was $116899.0 (down 26.82% YoY), and the annual figure for FY2025 was $116899.0, down 26.82%.
  • Total Non-Current Liabilities for Q4 2025 was $116899.0 at BioNexus Gene Lab, down from $126943.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $194615.0 in Q2 2024 to a low of $39659.0 in Q3 2022.
  • The 5-year median for Total Non-Current Liabilities is $85917.0 (2022), against an average of $100610.8.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 237.24% in 2023, then tumbled 33.89% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $65856.0 in 2021, then rose by 7.92% to $71072.0 in 2022, then skyrocketed by 56.2% to $111018.0 in 2023, then skyrocketed by 43.89% to $159741.0 in 2024, then decreased by 26.82% to $116899.0 in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $116899.0, $126943.0, and $141347.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.